CHARLESTON, SC--(Marketwired - Sep 4, 2013) - Afaxys Pharmaceuticals, a division of Afaxys, Inc., (www.afaxys.com/pharma) received FDA approval for two new oral contraceptives earlier this year, and now both are available to members of the Minnesota Multistate Contracting Alliance for Pharmacy (MMCAP). A Group Purchasing Organization (GPO), MMCAP serves city, county, and state healthcare facilities nationwide that provide healthcare services, such as state agencies, school districts and public higher education facilities. They do not serve non-governmental facilities.
The MMCAP GPO awarded a contract to Afaxys Pharmaceuticals in order to offer affordable oral contraceptives to its members. "We're proud to be partnered with MMCAP in their important mission, which parallels our goal of providing affordable access to public health providers," said Ronda Dean, CEO of Afaxys, Inc.
The two Afaxys Pharmaceuticals generic contraceptives now available through MMCAP are:
- Chateal® \shah•TEEL\ (Levonorgestrel and Ethinyl Estradiol tablets USP, 0.15 mg/0.03mg), and
- Lyza™ /LI•za/ (Norethindrone Tablets USP, 0.35 mg).
Both contraceptives are indicated for the prevention of pregnancy in women who elect to use an oral contraceptive for contraception. These products do not protect against the transmission of HIV (AIDS) and other sexually transmitted diseases. Cigarette smoking increases the risk of serious cardiovascular disease. Women who use oral contraceptives should be strongly advised not to smoke. Please see full prescribing information for Chateal (https://pharma.afaxys.com/afaxys/assets/pdf/Chateal_PI.pdf) and Lyza (https://pharma.afaxys.com/afaxys/assets/pdf/Lyza_PI.pdf).
Available only to the public health sector (including family planning clinics; college and university health centers; community health centers; and city, county, state, and federal facilities), and authorized, non-retail prescribers, Afaxys Pharmaceuticals products are now covered under most, if not all, fee for service Medicaid plans and commercial managed-care formularies.
What makes Afaxys Pharmaceuticals unique is its market segment: the company focuses solely on public health and safety net family planning providers, who have long been buffeted by soaring prices and product shortages.
Afaxys Pharmaceuticals aims to continue to provide high-priority contraceptive products, like Chateal and Lyza, at low costs to public health family planning providers. As additional contraceptive products become available the company plans to extend its core contraceptive formulary, allowing health centers to decrease high inventory costs by purchasing fewer products while still meeting their patients' needs.
Note: This press release was issued in the United States and is intended as reference information for U.S. journalists and customers. The information contained in this Afaxys press release is accurate at the time of issuance, and the company assumes no responsibility for updating the information to reflect subsequent developments.
Contact Information:
Media Contact
Colleen Troy